Alnylam vs. Ionis: Here's the Better Bad-News Buy
Alnylam cut its full-year revenue guidance due to slower-than-expected sales for Amvuttra. Ionis experienced two pipeline setbacks on the same day in July.
IONS - Ionis Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$84.38
DETAILS
HIGH:
$115.00
LOW:
$54.00
MEDIAN:
$85.00
CONSENSUS:
$84.38
UPSIDE:
91.25%
Stock News
NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido
Novartis wins FDA approval for Rhapsido in symptomatic dermographism, expanding its chronic hives opportunity as pipeline setbacks raise pressure for growth.
Ionis Pharmaceuticals (NASDAQ:IONS) Reaches New 52-Week Low – Should You Sell?
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) reached a new 52-week low on Monday. The stock traded as low as $42.80 and last traded at $43.2020, with a volume of 109956 shares changing hands. The stock had previously closed at $43.54. Wall Street Analyst Weigh In A number of brokerages have issued reports on
Contrasting Alector (NASDAQ:ALEC) & Ionis Pharmaceuticals (NASDAQ:IONS)
Alector (NASDAQ: ALEC - Get Free Report) and Ionis Pharmaceuticals (NASDAQ: IONS - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, earnings, dividends, profitability, valuation and risk. Institutional and Insider Ownership 85.8% of Alector shares are
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases.
Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs
IONS posts positive phase III results for two partnered drugs, with ulefnersen meeting its ALS endpoint and sefaxersen cutting proteinuria.
Ionis and Roche Advance First RNA-Targeted Therapy for Autoimmune Kidney Disease
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and licensing partner Roche Holdings AG (OTC:RHHBY) on Wednesday shared prespecified interim outcomes from their ongoing Phase 3 IMAgINATION trial of investigational sefaxersen in adults diagnosed with primary IgA nephropathy (IgAN).
Ionis announces positive interim data from partner Roche's Phase 3 IMAgINATION study in IgA nephropathy (IgAN)
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and partner Roche today announced positive prespecified interim results from the ongoing Phase 3 IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA nephropathy (IgAN). The study met its primary endpoint with sefaxersen achieving statistically significant and clinically meaningful improvements in proteinuria reduction, compared to placebo at 37 weeks, as measured by 24-hour urine protein.
Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Otsuka Pharmaceutical and Ionis Pharmaceuticals said on Tuesday their experimental drug met the main goal of a late-stage study in patients with a rare inherited form of amyotrophic lateral sclerosis, or ALS.
Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment
PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Ionis Pharmaceuticals, Inc. today announced positive topline results from the Phase 3 FUSION trial evaluating ulefnersen, an investigational RNA-targeted medicine, in people living with a genetic subtype of amyotrophic lateral sclerosis (ALS) known as FUS-ALS, caused by mutations in the fused in sarcoma (FUS) gene1. The study met its primary end.
Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Otsuka Pharmaceutical Development & Commercialization, Inc., today announced positive topline results from the Phase 3 FUSION trial evaluating ulefnersen, an investigational RNA-targeted medicine, in people living with amyotrophic lateral sclerosis (ALS) caused by mutations in the fused in sarcoma (FUS) gene, also known as FUS-ALS. The study met its primary endpoint, with ulefnersen demonstrating a statistical.
Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook
Ionis has six commercial therapies, mostly focused on rare diseases. Zanvastro treats Alexander disease, a brain disorder.
Ionis Pharmaceuticals Eyes TRYNGOLZA Growth as Pipeline Faces Cardio Setbacks
Ionis Pharmaceuticals NASDAQ: IONS CEO Brett Monia outlined recent regulatory wins, commercial-launch progress and several pipeline updates at the Morgan Stanley Global Healthcare Conference, while acknowledging setbacks in late-stage cardiovascular studies.
Ionis Pharmaceuticals, Inc. (IONS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Ionis Pharmaceuticals, Inc. (IONS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Ionis Pharmaceuticals, Inc. (IONS) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Ionis Pharmaceuticals, Inc. (IONS) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Cathie Wood Is Loading Up on Ionis Pharmaceuticals (IONS) Stock. Here's the Bet She's Making.
Cathie Wood has bought and sold the stock a lot, so don't follow her blindly. The company posted a loss in its last quarter, but revenue is growing robustly.
Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall
NVS' del-desiran fails the HARBOR study's primary endpoint, adding to recent pipeline setbacks as investors await next steps.
Ionis Pharmaceuticals (NASDAQ:IONS) Shares Gap Down After Analyst Downgrade
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) shares gapped down prior to trading on Tuesday after Morgan Stanley lowered their price target on the stock from $110.00 to $104.00. The stock had previously closed at $58.09, but opened at $52.15. Morgan Stanley currently has an overweight rating on the stock. Ionis Pharmaceuticals shares last
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling over 400 points on Tuesday.
Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners
On Tuesday, Novartis AG (NYSE:NVS) stock witnessed one of the sharpest single-day declines for the company in recent history.
Price Targets
Ionis Pharmaceuticals upgraded to Buy from Neutral at UBS
$88.00
(was $42.70)
UBS
Oppenheimer Reiterates Outperform Rating on Ionis Pharmaceuticals (IONS)
$85.00
(was $43.93)
Jay Olson
·
Oppenheimer
Ionis Pharmaceuticals (IONS) PT Lowered to $80 at Guggenheim
$80.00
(was $51.44)
Debjit Chattopadhyay
·
Guggenheim
Ionis Pharmaceuticals price target lowered to $85 from $90 at Barclays
$85.00
(was $56.71)
Barclays
Ionis Pharmaceuticals price target lowered to $84 from $87 at Raymond James
$84.00
(was $56.42)
Tiago Fauth
·
Raymond James
Ionis Pharmaceuticals price target lowered to $104 from $110 at Morgan Stanley
$104.00
(was $56.70)
Michael Ulz
·
Morgan Stanley
Ionis Pharmaceuticals price target lowered to $85 from $95 at Canaccord
$85.00
(was $58.09)
Canaccord Genuity
Ionis Pharmaceuticals price target lowered to $54 from $61 at BMO Capital
$54.00
(was $58.09)
BMO Capital
Ionis Pharmaceuticals price target lowered to $56 from $69 at Goldman Sachs
$56.00
(was $58.09)
Goldman Sachs
Ionis Pharmaceuticals price target raised to $61 from $60 at BMO Capital
$61.00
(was $58.13)
David Lebowitz
·
BMO Capital
Ionis Pharmaceuticals (IONS) PT Lowered to $115 at H.C. Wainwright
$115.00
(was $54.04)
Mitchell Kapoor
·
H.C. Wainwright
Ionis Pharmaceuticals price target raised to $69 from $66 at Goldman Sachs
$69.00
(was $54.04)
Goldman Sachs
Ionis Pharmaceuticals (IONS) PT Lowered to $89 at Guggenheim
$89.00
(was $52.95)
Debjit Chattopadhyay
·
Guggenheim
Ionis Pharmaceuticals price target lowered to $85 from $100 at RBC Capital
$85.00
(was $56.92)
Luca Issi
·
RBC Capital
Ionis Pharmaceuticals price target lowered to $110 from $130 at Morgan Stanley
$110.00
(was $59.89)
Morgan Stanley
Ionis Pharmaceuticals price target lowered to $95 from $110 at Canaccord
$95.00
(was $64.27)
Gary Nachman
·
Canaccord Genuity
Ionis Pharmaceuticals (IONS) PT Lowered to $90 at Barclays
$90.00
(was $64.27)
Eliana Merle
·
Barclays
Ionis Pharmaceuticals (IONS) PT Lowered to $90 at JefferiesMember Login
$90.00
(was $64.49)
Jefferies
Ionis Pharmaceuticals price target lowered to $86 from $105 at Needham
$86.00
(was $64.50)
Joseph Stringer
·
Needham
Ionis Pharmaceuticals price target lowered to $87 from $104 at Raymond James
$87.00
(was $64.29)
Raymond James